January 20, 2009 - Cambridge Research & Instrumentation (CRi) and VisEn Medical signed a non-exclusive agreement to enable CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America, in an effort to broaden the use of leading fluorescence in vivo imaging technologies, applications and standards in research and drug development.
CRi has a history of working in multi-spectral fluorescence in vivo imaging and fluorescence microscopy imaging systems, and reportedly has a significant customer base with a broad range of applications in life science research today. The distributor will bring in VisEn's fluorescent in vivo agents and labels to iCR’s Maestro multispectral fluorescence imaging system customers.
VisEn’s proprietary in vivo imaging agents and labels are designed to provide a robust and broad range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways in vivo, with several more new agents expected for launch in 2009. Key research areas enabled by the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease and pulmonary diseases, all in the context of the living animal.
VisEn’s agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro system with its powerful proprietary multispectral imaging technology. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.
For more information: www.visenmedical.com and www.cri-inc.com
April 18, 2024 
